We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

kindr currently serves patients in the United States only. Content is for informational purposes elsewhere.

Non-Hormonal Comparison · All 50 States

Non-hormonal alternatives to HRT: fezolinetant, SSRIs, gabapentin, CBT, and what actually works

Non-hormonal menopause treatments compared: fezolinetant, low-dose paroxetine, venlafaxine, gabapentin, oxybutynin, CBT and clinical hypnosis — effectiveness, side effects, and who each suits.

Start your visit — $79/mo →

← Hormone replacement therapy pillar

DIRECT ANSWER

When hormone therapy is contraindicated or unwanted, the options with the strongest evidence for hot flashes are fezolinetant (an NK3 receptor antagonist), low-dose paroxetine (the only FDA-approved non-hormonal drug for vasomotor symptoms until fezolinetant), venlafaxine or escitalopram, gabapentin for night-time symptoms, and cognitive behavioral therapy or clinical hypnosis. Non-hormonal options typically reduce hot flashes by 40–65 percent, compared with 75–90 percent for systemic estrogen.

Side-by-side comparison

OptionClassTypical doseBest suited toTrade-off
FezolinetantNK3 receptor antagonist45 mg dailyModerate-to-severe hot flashes with a hormone contraindicationLiver monitoring required; newer, costlier, coverage varies
Low-dose paroxetine mesylateSSRI (FDA-approved for VMS)7.5 mg nightlyHot flashes plus sleep disruptionDo not combine with tamoxifen (CYP2D6 inhibition)
Venlafaxine or escitalopramSNRI / SSRI (off-label)37.5–150 mg; 10–20 mgCoexisting mood symptomsNausea, sexual side effects, discontinuation symptoms
GabapentinAnticonvulsant (off-label)300–900 mg at bedtimeNight sweats and sleep-onset difficultySedation, dizziness; daytime dosing poorly tolerated
CBT or clinical hypnosisBehavioral4–8 structured sessionsBother and sleep impact; anyone avoiding medicationReduces distress and interference more than flush frequency; access varies
OxybutyninAnticholinergic (off-label)2.5–5 mg twice dailyRefractory vasomotor symptomsDry mouth; anticholinergic burden concerns with long-term use

Doses shown are typical starting ranges for context only. Your clinician sets your dose based on your history.

How clinicians actually choose

Frequently asked questions

What is the most effective non-hormonal treatment for hot flashes?

Fezolinetant and low-dose paroxetine have the strongest regulatory and trial support. Both reduce hot flash frequency and severity meaningfully, though less than systemic estradiol.

Do supplements work for hot flashes?

Most do not outperform placebo in randomized trials, including black cohosh, evening primrose oil, and red clover. Placebo response in menopause trials is high, which is why uncontrolled testimonials are misleading.

Can I use non-hormonal treatment and vaginal estrogen together?

Frequently yes. Vaginal estrogen has minimal systemic absorption and treats a different problem — genitourinary symptoms — than the systemic vasomotor treatments listed here.

Is non-hormonal treatment safer than HRT?

Not automatically. Every option here carries its own side-effect and monitoring profile. For most healthy women within 10 years of menopause, guideline bodies conclude the benefits of hormone therapy outweigh its risks.

Keep comparing

HRT for hot flashes →HRT for mood changes →Compare HRT providers →Estradiol Comparison →Progestogen Comparison →Testosterone & Perimenopause →

Not sure which option is right for you?

A board-certified clinician licensed in your state reviews your intake within one business day and recommends the route that fits your history — not a template.

Start your visit — $79/mo →

Comparing providers first? How to choose an HRT telehealth provider →

WRITTEN & MEDICALLY REVIEWED BY

Kindr Health Clinical Team

Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)

Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.

Organizational NPI 1609792902 · Last reviewed July 3, 2026 · Editorial policy

Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.

SOURCES & REFERENCES

Every clinical claim on this page is sourced.

  1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022) — The North American Menopause Society (NAMS). www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
  2. Clinical Practice Guideline: Treatment of Menopause-Associated Vasomotor Symptoms (2023) — American College of Obstetricians and Gynecologists (ACOG). www.acog.org/clinical/clinical-guidance/clinical-practice-guideline
  3. Menopause and hormone therapy: menopausal symptoms and treatments — NIH Office on Women’s Health. www.womenshealth.gov/menopause
  4. Menopausal Hormone Therapy and Cancer Risk — National Cancer Institute (NIH). www.cancer.gov/about-cancer/causes-prevention/risk/hormones/mht-fact-sheet
  5. Estradiol — drug label and prescribing information — U.S. Food & Drug Administration, DailyMed / NLM. dailymed.nlm.nih.gov/dailymed

Information on this page is for educational purposes only. Prescription medications require clinical evaluation and provider approval. Individual results vary. Not an emergency service.

Ask Dot